• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthmedicine

Joe Rogan’s highly questionable ivermectin COVID-19 ‘cure’ may be lethal. It’s also catching on around the world

By
Sophie Mellor
Sophie Mellor
Down Arrow Button Icon
By
Sophie Mellor
Sophie Mellor
Down Arrow Button Icon
September 2, 2021, 6:38 AM ET

Ivermectin is an antiparasitic pill mainly used to deworm horses and cows. It is also, according to podcast star Joe Rogan, a great way to treat COVID-19.

Even before the endorsement from Rogan, who recently came down with COVID-19 and treated it with a cocktail of drugs unproven to be effective against the illness, ivermectin had been growing in popularity. In places like Brazil, Bolivia, Peru, and South Africa—along with the U.S.—people were using it to self-medicate against COVID-19.

Google searches for ivermectin are at an all-time high. Searches for ivermectin jumped alongside other at-home remedies like “hydroxychloroquine” at the start of the pandemic in March 2020, but while the Trump-backed hydroxychloroquine fell out of favor, ivermectin maintained its popularity. Prescriptions for ivermectin jumped to more than 88,000 in the week ended Aug. 13, and some pharmacists have even reported shortages of the drug.

But as with many unproven medicines, it can have fatal consequences.

Calls to poison control centers about ivermectin exposures have risen fivefold over the baseline in July, according to CDC researchers who used data from the American Association of Poison Control Centers.

Mississippi’s health department even issued an alert in August saying 70% of recent calls to the state poison control center had come from people who over-ingested ivermectin from livestock supply stores.

Such dangerous effects from self-prescription have prompted Merck, the manufacturer of the drug, to come out and say there was no scientific basis for ivermectin to be used as treatment against COVID-19 and the Food and Drug Administration to caution against ingestion of the medicine, warning that “using the drug ivermectin to treat COVID-19 can be dangerous and even lethal.”

Beyond ivermectin’s potential dangers, the drug also appears to offer little benefit in the fight against COVID. Researchers looking into the efficacy of ivermectin as a COVID-19 treatment had to shut down a large 1,300 patient trial because the drug had been no better than a placebo at preventing hospitalizations. Dr. Edward Mills, a professor at McMaster University who led the study, noted the team would have discontinued it earlier were it not for the level of public interest in ivermectin.

Researchers and physicians are particularly worried by people who are seeking out ivermectin to prevent COVID-19 in lieu of getting a vaccine.

But this has not stopped Rogan, the popular podcast host who has already been in hot water for suggesting young, fit people don’t need to get the COVID-19 vaccine.

After announcing a few canceled tour dates owing to his illness, Rogan gave a shout-out to the medicine, saying “a wonderful, heartfelt thank you to modern medicine for pulling me out of this so quickly and so easily.”

https://www.instagram.com/p/CTSsA8wAR2-/

Instagram captioned his post with a short warning: “Some unapproved COVID-19 treatments may cause serious harm.”

Facebook, owner of Instagram, did not respond to requests for comment.

Subscribe to Fortune Daily to get essential business stories straight to your inbox each morning.
About the Author
By Sophie Mellor
See full bioRight Arrow Button Icon

Latest in Health

HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
3 hours ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
4 hours ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
6 hours ago
Healthmeal delivery
Factor Meals Review 2025: Tester Approved
By Christina SnyderDecember 12, 2025
21 hours ago
Donald Trump
HealthHealth Insurance
‘Tragedy in the making’: Top healthcare exec on why insurance will spike to subsidize a tax cut to millionaires and billionaires
By Nick LichtenbergDecember 12, 2025
22 hours ago
HelloFresh meal delivery service.
Healthmeal delivery
HelloFresh Review : We Tasted Everything so You Don’t Have To
By Christina SnyderDecember 12, 2025
23 hours ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
For the first time since Trump’s tariff rollout, import tax revenue has fallen, threatening his lofty plans to slash the $38 trillion national debt
By Sasha RogelbergDecember 12, 2025
22 hours ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
21 hours ago
placeholder alt text
Success
At 18, doctors gave him three hours to live. He played video games from his hospital bed—and now, he’s built a $10 million-a-year video game studio
By Preston ForeDecember 10, 2025
3 days ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.